Abstract: The present disclosure provides a display panel and a display device, pertains to the field of display technologies. The present disclosure provides a display panel at least including a display region. The display panel includes a base substrate and a plurality of sub-pixels disposed on the base substrate, a sub-pixel at least includes a light emitting device, and the light emitting device is located in the display region. The light emitting device includes a first electrode, a light emitting layer, and a second electrode provided in sequence in a direction facing away from a base substrate. The display panel further includes a heat conduction structure disposed on a side of the first electrode facing away from the light emitting layer, and orthographic projections of the heat conduction structure and the first electrode on the base substrate are at least partially overlapped with each other.

Abstract: A vehicle handrail assembly includes: a mounting base and a rotating handrail. The rotating handrail includes a fixing rod and a movable rod. The fixing rod is rotatably connected to the mounting base along a first rotating axis extending in a first direction of a vehicle and a second rotating axis extending in a second direction of the vehicle, where the first direction is perpendicular to the second direction. The movable rod is movably connected to the fixing rod along the length direction of the rotating handrail. The rotating handrail switches between a use state and a retracted state. In the use state, the rotating handrail extends along the first direction, and in the retracted state, the rotating handrail extends along the second direction.

Abstract: A method for screening tobacco resistance against root-knot nematode based on intensive seedling production is provided. The method has two biological properties: inducing and stimulating the hatching of nematode eggs by host root exudates, and easily infecting the root cap elongation zone by hatched second-instar larvae. The second-instar larvae hatched by the root-knot nematode eggs are continuously inoculated. After that, under cultivating the infected tobacco seedlings in shallow water infiltrating and humidifying substrate, the created temperature, humidity and air permeability conditions are suitable for disease induction. After disease investigation, disease index is calculated, and the resistance of tested cultivars is evaluated according to the disease index. The method features simple operation, high selection efficiency, and high accuracy and reproducibility.

Abstract: A carriage comprises a carriage body (1) consisting of a top frame, side walls, and a bottom frame. An end wall (2) is disposed on at least one end of the carriage body (1). Connectors (3) are symmetrically disposed on the left side and the right side of an outer wall body of the end wall (2). All the connectors (3) disposed on the end wall (2) of the carriage are connected by means of lines. The carriages can be grouped into each train in a meal ordering manner. When each carriage is added into a high-speed train set, the arrangement of the carriage is not limited, and accordingly, the carriage can be added into the train without limitation. On the premise the of ensuring the normal work of systems of the train, the work amount of staff members in a group can be reduced, and the work time of the staff members in the group is shortened.

Abstract: The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2? value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.

Abstract: The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.

Abstract: The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2? value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.

Abstract: The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: A carriage comprises a carriage body (1) consisting of a top frame, side walls, and a bottom frame. An end wall (2) is disposed on at least one end of the carriage body (1). Connectors (3) are symmetrically disposed on the left side and the right side of an outer wall body of the end wall (2). All the connectors (3) disposed on the end wall (2) of the carriage are connected by means of lines. The carriages can be grouped into each train in a meal ordering manner. When each carriage is added into a high-speed train set, the arrangement of the carriage is not limited, and accordingly, the carriage can be added into the train without limitation. On the premise the of ensuring the normal work of systems of the train, the work amount of staff members in a group can be reduced, and the work time of the staff members in the group is shortened.

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.

Abstract: The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetra-cyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.